Juno is led by a team of highly skilled experts, with decades of collective industry experience to drawn on, they offer a breadth of pharmaceutical knowledge. This knowledge paired with a genuine passion for innovation and to drive value consistently delivers superior outcomes for suppliers, customers and shareholders alike.

Ian Jacobson
Chief Executive Officer

Ian has over 35 years of pharmaceutical industry experience. Prior to founding Juno, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010, he was also instrumental in the development of Arrow’s other international business units. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Actavis) in June 2009 for over $2.4 billion USD. Prior to his work at Arrow, Ian was an executive at Par Pharmaceuticals (US) in the Office of the President, Gingham Canada as Executive Vice President and Amerpharm/Merck KGaA as a Senior Executive in the international generics business.

Read more

Craig Podolsky
President

Craig has over 15 years of pharmaceutical industry experience. Prior to co-founding Juno in 2011, Craig worked for Cobalt Pharmaceuticals in its business development group. He was responsible for negotiating product license and supply agreements for Cobalt’s OTC and generic divisions, and was Cobalt’s primary lead on all global M&A transactions.

Read more

Chris Ichiyen, CPA, CA
Vice President of Finance

Chris has 14 years of pharmaceutical industry experience working most recently with Cannabis Compliance Inc. (“CCI”) as their Vice President of Finance in the burgeoning Canadian Cannabis industry from 2018 to 2019. Prior to CCI he worked as the Canadian Finance Country Head with Actavis Pharma as a member of the leadership team managing cross-functional initiatives in a complex and results oriented environment. During that time he gained experience in mergers and acquisitions and post acquisitions integration including in-depth support on $1.8 billion of transactions. Chris earned his CPA/CA while at KPMG.

Read more

Andrew Brown
Head of Intellectual Property

Andrew Brown is a Chartered UK and European Patent Attorney with over 20 years of pharmaceutical industry experience. Before joining Juno in 2016, Andrew served as the Head of IP at Pharmathen, and prior to that he served in a number of high profile IP roles at various leading pharmaceutical companies, including Senior Patent Attorney at AstraZeneca and IP Director at Teva.

Read more

Jesse Buckstein
Director of Corporate Development

Jesse joined Juno in 2014 and has over 10 years of corporate finance and pharmaceutical experience. Prior to joining Juno, Jesse worked in corporate finance, serving across a number of debt financing, private equity, and public asset management-focused roles. A passionate champion of – and investor in – local medical technology companies, Jesse co-founded SNG Hawk’s Nest in 2017 and currently serves as the chief investment officer of Springbuck Capital, a private local venture fund that holds minority equity interests in the likes of Cyclica, Intellijoint Surgical, Synaptive Medical, Trexo Robotics and others.

Read more